Changing the way healthcare is done for CID’s.
We specialise in precision medicine solutions to enable early detection, prevention, and treatment of chronic inflammatory diseases (CIDs). 4.5Bn of the 7.6Bn humans currently alive are expected to get sick and die due to a CID. The WFO estimates that the global costs of just four chronic diseases – cancer, diabetes, heart disease and respiratory disease – all of which are characterised by CI processes will reach $47 trillion / year by 2030. Current medicine for CIDs acts late in disease progression. It is imprecise with many therapies being focussed on alleviating symptoms rather than tackling underlying causes. And it is also very expensive.
What’s the innovation?
GlyHealth, is our unique, innovative technology addressing the constraints of current medicine for CIDs by enabling early detection, identification and tracking of these conditions. This allows early action using therapeutic regimes to mitigate CID progression and severity before tissue and organ damage can occur thus reduce people suffering and provide huge financial savings to society.
What are you looking to get from #VFS20?
At this year’s #VFS20, we are mainly looking to meet potential investors and collaborators.